A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 450
- Registration Number
- NCT06513884
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT06430905
- Locations
- 🇺🇸
Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Orlando Immunology Center (OIC), Orlando, Florida, United States
🇺🇸The Hope Clinic at Emory University, Decatur, Georgia, United States
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 12
- Registration Number
- NCT05553639
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸California Cancer Associates for Research & Excellence (cCARE), San Marcos, California, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 10
- Registration Number
- NCT04630353
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
- Conditions
- Interventions
- Drug: HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.Drug: HB-202 / HB-201 alternating intravenous administration + pembrolizumab.Drug: HB-201 intravenous administration.Drug: HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)Drug: HB-201 intravenous administration + standard of care regimen including pembrolizumab.Drug: HB-202 intravenous administration alternating with HB-201 intravenous administration.
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 200
- Registration Number
- NCT04180215
- Locations
- 🇺🇸
O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Cancer Institute, Clinical Trials Office, Fayetteville, Arkansas, United States
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 83
- Registration Number
- NCT03629080
- Locations
- 🇺🇸
South Texas Accelerated Research, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇬🇧St James's University Hospital, Leeds, United Kingdom
Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV
- Conditions
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 54
- Registration Number
- NCT02798692
- Locations
- 🇧🇪
Center for Vaccinology Ghent, Ghent, East Flanders, Belgium